Despite widespread heap of immunotherapy in oncology society in recent years, rectal cancer remains somewhat sanctuary to this trend with somewhat limited, if not negligible use of the contemporary PD-1/PD-L1 blockade. The gene discussed is PDCD1; the disease is rectal cancer.